Currently, the disease is usually found too late to save lives
Reporting on a small preliminary study, Johns Hopkins researchers say a simple blood test based on detection of tiny epigenetic alterations may reveal the earliest signs of pancreatic cancer, a disease that is nearly always fatal because it isn’t usually discovered until it has spread to other parts of the body.
The findings of their research, if confirmed, they say, could be an important step in reducing mortality from the cancer, which has an overall five-year survival rate of less than 5 percent and has seen few improvements in survival over the last three decades.
“We have mammograms to screen for breast cancer and colonoscopies for colon cancer but we have had nothing to help us screen for pancreatic cancer,” says Nita Ahuja, M.D., an associate professor of surgery, oncology and urology at the Johns Hopkins University School of Medicine and leader of the study described online this month in the journal Clinical Cancer Research. “While far from perfect, we think we have found an early detection marker for pancreatic cancer that may allow us to locate and attack the disease at a much earlier stage than we usually do.”
For their study, Ahuja and her colleagues were able to identify two genes, BNC1 and ADAMTS1, which together were detectable in 81 percent of blood samples from 42 people with early-stage pancreatic cancer, but not in patients without the disease or in patients with a history of pancreatitis, a risk factor for pancreatic cancer. By contrast, the commonly used PSA antigen test for prostate cancer only picks up about 20 percent of prostate cancers.
Ahuja and her colleagues found that in pancreatic cancer cells, it appears that chemical alterations to BNC1 and ADAMTS1 — epigenetic modifications that alter the way the genes function without changing the underlying DNA sequence — silence the genes and prevent them from making their protein product, the role of which is not well-understood. These alterations are caused by the addition of a methyl group to the DNA.
Using a very sensitive method called Methylation on Beads (MOB) developed by Jeff Tza-Huei Wang, Ph.D., a professor at the Whiting School of Engineering at Johns Hopkins, the researchers were able to single out, in the blood, even the smallest strands of DNA of those two genes with their added methyl groups. The technique uses nanoparticle magnets to latch on to the few molecules being shed by the tumors, which are enough to signal the presence of pancreatic cancer in the body, the researchers found.
Specifically, researchers say, they found BNC1 and ADAMTS1 in 97 percent of tissues from early-stage invasive pancreatic cancers. Surgery is the best chance for survival in pancreatic cancer, because radiation and chemotherapy are not very effective against it. The smaller the cancer — the earlier it is detected — the more likely surgery will be successful and the patient will survive.
Ahuja says the practical value of any blood test for cancer markers depends critically on its sensitivity, meaning the proportion of tumors it detects, and its specificity, meaning how many of the positive results are false alarms. The specificity of this new pair of markers is 85 percent, meaning 15 percent would be false alarms. Ahuja says she hopes further research will help refine the test, possibly by adding another gene or two, in order to go over 90 percent in both sensitivity and specificity.
Ahuja also cautions that her team still needs to duplicate the results in a larger sample of tumors, but is encouraged by the results so far. She says she doesn’t envision the blood test as a means of screening the general population, the way mammograms and colonoscopies are used to find early breast and colon cancers. Instead, she imagines it would be best used in people at high risk for developing the disease, such as those with a family history of pancreatic cancer, a previous case of pancreatitis, long-term smokers or people with the BRCA gene mutations, which are linked to breast, ovarian and pancreatic cancers.
“You have to optimize your medical resources,” says Ahuja, who hopes a commercial blood test might one day only cost $50.
Go deeper with Bing News on:
- BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EUon January 15, 2020 at 4:52 pm
lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.
- Local organization wants people to watch for potential warning signs of pancreatic canceron January 15, 2020 at 6:31 am
CHARLOTTE, N.C. — Around 57,000 people will be diagnosed with pancreatic cancer this year. Another 47,000 will lose their battles. November is pancreatic cancer awareness month, but the Charlotte ...
- Pancreatic Cancer Symptoms: The Dangerous Pee Coloron January 15, 2020 at 1:18 am
Pancreatic cancer may not be very common as lung cancer or bowel cancer, but it is also one of those that you must be aware of. One of the symptoms of this kind of cancer is shown in the color of your ...
- Organoids for the study of pancreatic cancer with David Tuvesonon January 14, 2020 at 4:00 pm
Dr. Tuveson is The Cancer Center Director and the Director of the Cancer Therapeutics Initiative at Cold Spring Harbor Laboratory and the Chief Scientist for the Lustgarten Foundation for Pancreatic ...
- BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europeon January 14, 2020 at 4:06 am
Before it's here, it's on the Bloomberg Terminal.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Pancreatic cancer blood test
- Ruth Bader Ginsburg Says She No Longer Has Pancreatic Canceron January 8, 2020 at 3:54 pm
Justice Ginsburg, 86, underwent treatment for a malignant tumor that was discovered after a blood test in July. Justice Ruth Bader Ginsburg, whose health has become a preoccupation of the American ...
- Early detection of pancreatic cancer evades patients, doctorson December 31, 2019 at 5:07 am
For cases of tumors on blood vessels that can ... include no effective screening test, mild effectiveness of chemotherapy treatment, and a need for better understanding of the biology of pancreatic ...
- Rep. John Lewis and Alex Trebek have pancreatic cancer. What are symptoms, treatments?on December 30, 2019 at 8:42 am
host Alex Trebek were diagnosed with stage 4 pancreatic cancer. The disease affects the pancreas, the small organ in the upper part of the backside of the abdomen — between the stomach and the spine — ...
- LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-MutatedMetastatic Pancreatic Canceron December 30, 2019 at 2:55 am
AstraZeneca and Merck MRK, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has ...
- LYNPARZA (Olaparib) Approved in the US as a 1st-line Maintenance Treatment of Germline BRCA-mutated Metastatic Pancreatic Canceron December 30, 2019 at 2:55 am
Results showed a statistically significant and clinically meaningful improvement in progression-free survival, where LYNPARZA nearly doubled the time patients with gBRCAm metastatic pancreatic cancer ...